Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Refractory Lymphoplasmacytic Lymphoma

Known as: Refractory Lymphoplasmacytoid Lymphoma/Immunocytoma 
Lymphoplasmacytic lymphoma resistant to treatment.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
We examined the combination of the mammalian target of rapamycin inhibitor everolimus with bortezomib and rituximab in patients… Expand
  • figure 1
  • table 1
  • table 1
  • table 3
  • figure 2
Is this relevant?
2012
2012
A 64-year-old man with a 2-week history of fatigue and fever presented to the medical admissions unit. He had a background of… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2008
2008
INTRODUCTION: Perifosine is an oral, novel synthetic alkylphospholipid, with multiple effects on signal transduction pathways… Expand
Is this relevant?
2008
2008
8535 Background: This phase II study aimed to determine safety and activity of weekly bortezomib in combination with rituximab in… Expand
Is this relevant?